What’s Going On With Ford Stock Today?
Ford Motor Co (NYSE: F) shares are moving higher Thursday after the company updated some financial targets and announced changes to its reporting structure ahead of its
Evoke Pharma & EVERSANA Announce Compelling Real-World Data On The Impact Of GIMOTI In Reducing The Utilization Of Healthcare Resources To Be Presented At The Academy Of Managed Care Pharmacy 2023
Evoke Pharma, Inc. (NASDAQ:EVOK),a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and
NY Gov Hochul’s Latest Crackdown On Illicit Cannabis Operations Has The Big Apple In Its Crosshairs
New York authorities would be given expanded power to shut down illegal pot shops and levy fines of up to $200,000 under legislation proposed Wednesday by Gov. Kathy Hochul, who is making yet another attempt to protect the stalled legal weed market.
EXCLUSIVE: Cannabis Industry Leaders React To Twitter’s Embrace Of Cannabis Advertising
Twitter’s decision to allow ads for CBD and THC products on its platform was a hot topic during the "Benzinga Live" show on Wednesday, which featured guests who will be speaking at the upcoming Benzinga Cannabis
The Evolution Of Social Drinking: Beverage Companies Dip Their Toes Into Cannabis
Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies outside the cannabis industry have been adding or exploring cannabis partnerships and products.
Incyte Announced Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo; Said Patients Treated With Povorcitinib Experienced Improvements In Total Body And Facial Repigmentation
Incyte (Nasdaq: INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
Connect Biopharma Announced CBP-201 Atopic Dermatitis China Pivotal Study Met Primary And Secondary Endpoints
Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.
TerrAscend Reports Record Q4 Revenue Increase Of 4% Sequentially & Full Year 2022 Highlights
TerrAscend Corp. (OTCQX: TRSSF) reported its financial results Thursday afternoon for the fourth quarter and full year ended December 31, 2022.
Q4 financial highlights include:
Isiah Thomas: From NBA Champ To Business Mogul, Hemp Cars, CBD Drinks & Champagne Producer
NBA Hall of Famer and sports legend-turned-cannabis entrepreneur Isiah Thomas knows how to make his dreams come to life.
Reported Late Tuesday March 14, Deciphera Pharmaceuticals Announces QINLOCK Included In NCCN Guidelines For The Treatment Of Second-Line GIST Patients And FDA Grants Breakthrough Therapy Designation For QINLOCK In Second-Line GIST Patients With Mutatio…
– NCCN Guidelines Include QINLOCK as a Preferred Regimen for Second-Line GIST Patients Intolerant to Sunitinib –